Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“Since only 30%–50% of colorectal cancers have KRAS mutations [4,18,21], there has been speculation that the detection of KRAS mutation may portend a worse prognosis.”
BackgroundHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095 · cited 1×
“addition, miRNA expression is often lost in cancer because they tend to be located in genomic regions that are frequently lost during cancer development [67].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 4×
“The reduced expression of let-7 in cancer tissues corresponds to significantly higher levels of KRAS mRNA [70].”
BackgroundInfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690 · cited 1×
“Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Cited by
Items 101–200 of 252
Polysystemic Approach to School, Sport and Environment Medicine
(2014) · OMICS International eBooks · doi:10.4172/978-1-63278-000-3-001 · Cited by 13
KRAS mutations in patients with colorectal cancer in Libya
Abudabous, A., Drah, M. M., Aldehmani, M., Parker, I. M., & Alqawi, O. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2359 · Cited by 14
Insight of microRNA role in Colorectal Cancer
Lye, K. L., Tan, L. T., & Yap, H. M. (2020) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000083 · Cited by 14
Target Genetic Abnormalities for the Treatment of Colon Cancer and Its Progression to Metastasis
Baviskar, T., Momin, M. M., Liu, J., Guo, B., & Bhatt, L. K. (2020) · Current Drug Targets · doi:10.2174/1389450121666201119141015 · Cited by 13
TCGA database analysis of the tumor mutation burden and its clinical significance in colon cancer
Chen, J., Apizi, A., Wang, L., Wu, G., Zhu, Z., Yao, H., Chen, G., Shi, X., Shi, B., Tai, Q., et al. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-661 · Cited by 13
“Similarly, when KRAS is mutated, the downstream signaling pathway (mitogenactivated protein kinase, MAPK) is activated, leading to cell proliferation and tumor progression (41,42).”
BackgroundAlghamdi, M., Alabdullatif, N., Al-Rashoud, A., Alotaibi, J., Alhussaini, N., Elsirawani, S., Somily, H., Alkhudair, N. A., AlOtaiby, M., Ahamed, S. S., et al. (2022) · Cureus · doi:10.7759/cureus.23656 · Cited by 14
Colorectal cancers with a residual adenoma component: Clinicopathologic features and KRAS mutation
Lee, H. W., Song, B., & Kim, K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273723 · Cited by 10
Dolatkhah, R., Somi, M. H., Kermani, I. A., Bonyadi, M. J., Sepehri, B., Boostani, K., Azadbakht, S., Fotouhi, N., Farassati, F., & Dastgiri, S. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s116373 · Cited by 11
Kim, B., Lee, S., & Moon, K. C. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.09.011 · Cited by 12
Majrashi, T. A., Sabt, A., Almahli, H., Hassab, M. A. E., Noamaan, M. A., Elkaeed, E. B., Hamissa, M. F., Maslamani, A. N. J., Shaldam, M. A., & Eldehna, W. M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300035 · Cited by 11
The Correlation of KRAS Gene Expression and P53 Immunoexpression In Colorectal Adenocarcinoma
Rachmawati, M., Yulianti, H., Hernowo, B. S., Suryanti, S., Wijaya, I., Rahadiani, N., Heriyanto, D. S., & Irianiwati, I. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.549 · Cited by 11
“9% of ADCCR cases in this study had a good response to anti-EGFR, such as cetuximab and panitumumab [1], [3], [11], [18].”
BackgroundInfluentialFeng, Q., Liang, L., Ren, L., Chen, J., Wei, Y., Chang, W., Zhu, D., Lin, Q., Zheng, P., & Xu, J. (2015) · Europe PMC (PubMed Central) · Cited by 14
Liang, L., Tian, J., Yu, Y., Wang, Z., Peng, K., Liu, R., Wang, Y., Xu, X., Li, H., Zhuang, R., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494242 · Cited by 12
Inducible Liver Cancer Models in Transgenic Zebrafish to Investigate Cancer Biology
Lee, A. Q., Li, Y., & Gong, Z. (2021) · Cancers · doi:10.3390/cancers13205148 · Cited by 10
KRAS is a prognostic biomarker associated with diagnosis and treatment in multiple cancers
Da, Z., Wang, L., Chen, Z., Zhang, L., & Xu, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1024920 · Cited by 10
“The abnormal activation of GTP binding of mutated KRAS protein leads to the unregulated growth of downstream cells (Arrington et al., 2012).”
BackgroundWang, L., Lin, S., Yang, C., Cai, S., & Li, W. (2022) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1905 · Cited by 11
abadi, Z. M. A., Rad, F. S., Asl, D. H., Rahmani, B., Dodaran, M. S., & Peimani, A. (2022) · Iranian journal of pathology · doi:10.30699/ijp.2021.531779.2653 · Cited by 10
“Studies have shown that mutations in the KRAS gene, in addition to causing resistance to targeted therapies with cetuximab and panitumumab, also have a significant effect on the prognosis of the disease (15, 16).”
BackgroundPrognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma
Palomba, G., Cossu, A., Paliogiannis, P., Pazzola, A., Baldino, G., Scartozzi, M., Ionta, M. T., Ortu, S., Capelli, F., Lanzillo, A., et al. (2016) · Oncology Letters · doi:10.3892/ol.2016.4798 · Cited by 10
“Approximately 30‑50% of CRC patients have KRAS mutations, and they are associated with poor responsiveness to anti-EGFR antibody therapies (7-10 , 15).”
Targeting the HER2-ELF3-KRAS axis: a novel therapeutic strategy for KRASG13D colorectal cancer
Hwang, S., Seo, Y., Park, S., Kim, S.-A., Moon, I., Liu, Y., Kim, S., Pak, E. S., Jung, S., Kim, H., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02343-5 · Cited by 11
“Despite the association of KRAS G13D with a worse prognosis compared to other KRAS subtypes [29, 58, 59], there are minimal studies proposing effective therapeutic strategies for KRAS G13D , and direct specific inhibitors for KRAS G13D are not yet available [60].”
Italiano, A., Gautier, O., Dupont, J., Assi, T., Dawi, L., Lawrance, L., Bône, A., Jardali, G., Choucair, A., Ammari, S., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115609 · Cited by 12
Tariq, L., Arafah, A. M., Sehar, N., Ali, A., Khan, A., Rasool, I., Rashid, S. M., Ahmad, S. B., Beigh, S., Dar, T. U. H., et al. (2023) · Medical Oncology · doi:10.1007/s12032-023-02099-2 · Cited by 9
Kim, J. K., Marco, M. R., Choi, S., Qu, X., Chen, C., Elkabets, M., Fairchild, L., Chow, O. S., Barriga, F. M., Dow, L. E., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12960 · Cited by 10
Self-citationGold nanoprobes for detecting DNA adducts
Trantakis, I. A., & Sturla, S. J. (2014) · Chemical Communications · doi:10.1039/c4cc07184k · Cited by 9
Tumor Protein p53 and K-ras Gene Mutations in Peruvian Patients with Gallbladder Cancer
Vidaurre, T., Casavilca-Zambrano, S. A., Montenegro, P. C., Gómez, H., Calderón, M. J., Navarro, J. M., Palomino, J. I. A., Poquioma, E., Tsuchiya, Y., Asai, T., et al. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.1.289 · Cited by 9
“K-ras is a proto-oncogene that exerts control in the mechanisms of cell growth and differentiation (Arrington et al., 2012).”
BackgroundGlobal metabolomics revealed deviations from the metabolic aging clock in colorectal cancer patients
Zhang, L., Mo, S., Zhu, X., Chou, C. J., Jin, B., Han, Z., Schilling, J., Liao, W., Thyparambil, S. P., Luo, Y. R., et al. (2024) · Theranostics · doi:10.7150/thno.87303 · Cited by 9
“Clinically, KRAS and BRAF mutations are associated with a poor prognosis [29, 30].”
BackgroundGenomic profiling of microRNA target genes in colorectal cancer
Fadaka, A. O., Bakare, O. O., Pretorius, A., & Klein, A. (2020) · Tumor Biology · doi:10.1177/1010428320933512 · Cited by 8
“The RAS oncogene has a well-defined role in cell growth and regulation, and its protein product affects many cellular functions including cell proliferation, apoptosis, migration, fate specification, and differentiation.(47) KRAS has been reported to be the most frequently altered gene, with mutations occurring in 17%…”
BackgroundOvercoming EGFR Resistance in Metastatic Colorectal Cancer Using Vitamin C: A Review
Machmouchi, A., Chehade, L., Temraz, S. N., & Shamseddine, A. I. (2023) · Biomedicines · doi:10.3390/biomedicines11030678 · Cited by 8
“Combination chemotherapy has been regarded as the cornerstone for mCRC management [9].”
Backgroundp21-activated kinase family: promising new drug targets
He, H. Z., & Huynh, N. T. (2015) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s57278 · Cited by 11
“45,46,48 Mutations of Kras cause deregulated cell growth, migration, apoptosis, and differentiation via activation of its downstream effectors.”
Makkai-Popa, S. T., Luncă, S., Târcoveanu, E., Carasevici, E., & Dimofte, G. (2014) · PubMed · Cited by 8
Kim, J. H. (2016) · The Analyst · doi:10.1039/c6an00909c · Cited by 8
Self-citationClevenger, A. J., Collier, C. A., Gorley, J. P. M., Colijn, S., McFarlin, M. K., Solberg, S. C., Kopetz, S., Stratman, A. N., & Raghavan, S. A. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0624 · Cited by 9
Sitthisuk, P., Innajak, S., Poorahong, W., Samosorn, S., Dolsophon, K., & Watanapokasin, R. Y. (2024) · Nutrients · doi:10.3390/nu16213764 · Cited by 7
Mulla, N., Alshareef, A., Syed, A. R., & Al-Jahel, M. (2020) · Cureus · doi:10.7759/cureus.9978 · Cited by 8
“Percentage of K-ras mutations, which are known to work as an activated oncogene, occurs in 35%-45% of CRC worldwide [6,11,16].”
BackgroundGenomic and immunological features of microsatellite instability in colon cancer
Luo, Y., Zhou, Y., Chen, Y., Lu, X., & Quan, Y. (2021) · Gene · doi:10.1016/j.gene.2021.145534 · Cited by 7
Alias, N. A. R., Hoo, W. P. Y., Siak, P. Y., Othman, S. S., Alitheen, N. B., In, L. L. A., Rahim, R. A., & Song, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108928 · Cited by 7
Rare case of triple mutant (KRAS + NRAS + BRAF) metastatic colon adenocarcinoma
Vittal, A., Sharma, D., Samanta, I., & Kasi, A. (2019) · BMJ Case Reports · doi:10.1136/bcr-2017-221816 · Cited by 8
Rasool, M., Carracedo, Á., Sibiany, A., Al-Sayes, F., Karim, S., Haque, A., Pushparaj, P. N., Asif, M., & Achakzai, N. M. (2021) · Bioengineered · doi:10.1080/21655979.2021.1960715 · Cited by 7
Awi, N. J., Yap, H.-Y., Armon, S., Low, J. S.-H., Peh, K.-B., Peh, S. C., Lee, C. S., & Teow, S. (2021) · PubMed · Cited by 8
Prognostic gene expression profile of colorectal cancer
Saadh, M. J., Allela, O. Q. B., Kareem, R. A., Baldaniya, L., Ballal, S., Vashishth, R., Parmar, M., Sameer, H. N., Hamad, A. K., Athab, Z. H., et al. (2025) · Gene · doi:10.1016/j.gene.2025.149433 · Cited by 6
Loss of HES-1 Expression Predicts a Poor Prognosis for Small Intestinal Adenocarcinoma Patients
Kim, J. W., Jun, S., Ylaya, K., Chang, H., Oh, Y., Hong, S., Chung, J., & Hewitt, S. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01427 · Cited by 6
Self-citationJauhri, M., Gupta, V. K., Shokeen, Y., Minhas, S., Bhalla, S., & Aggarwal, S. (2017) · Journal of Next Generation Sequencing & Applications · doi:10.4172/2469-9853.1000148 · Cited by 6
“The association of the disease with commonly occurring genetic mutations like those in KRAS, BRAF and PIK3CA has been shown in various studies [5-7] but less attention has been given to the role and correlation of genetic mutations which occur rarely such as those in KDR, PTEN, SMAD4 and others.”
BackgroundDahlmann, H. A., Berger, F. D., Kung, R. W., Wyss, L. A., Gubler, I., McKeague, M., Wetmore, S. D., & Sturla, S. J. (2018) · Helvetica Chimica Acta · doi:10.1002/hlca.201800066 · Cited by 6
Fard, G. B., Amirfakhrian, R., Bafghi, M. H., & Gholamin, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04097-y · Cited by 5
“Approximately 30–40% of colon cancers have mutations in the KRAS oncogene [43].”
Exploration of Kras Mutations and Their Potential for Being a Target Molecule in Cancer Chemotherapy
Chinthareddy, A., & Oroszi, T. L. (2023) · Journal of Cancer Therapy · doi:10.4236/jct.2023.146022 · Cited by 5
Song, J., Wang, B., Zou, M., Zhou, H., Ding, Y., Ren, W., Fang, L., & Zhang, J. (2025) · Biology · doi:10.3390/biology14050477 · Cited by 5
“[3], cholangiocarcinoma (CHOL, ~27”
The prevalence of KRAS and BRAF mutation in colorectal cancer patients in Bali
Nyoman, A. D. N., Suksmarini, N. M. P. W., Pranata, A. A. N. S., Rompis, A. Y., & Sumadi, I. W. J. (2022) · Indonesian Journal of Biotechnology · doi:10.22146/ijbiotech.67506 · Cited by 5
“The RASCAL study (Arrington et al. 2012) reported mutations in codon 12 in 27.7% of cases.”
BackgroundMethodResultInfluentialMastutik, G., Rahniayu, A., Rahaju, A. S., Kurniasari, N., & I’tishom, R. (2018) · INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY · doi:10.24293/ijcpml.v23i1.1177 · Cited by 8
Park, J. S., Lee, S. S., & Choi, Y. S. (2024) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2024.25.7.2337 · Cited by 4
“KRAS gene mutations occur in 17–25% of all cancers [1].”
BackgroundOxidative Stress Assessment in Colorectal Cancer Patients: Erbil Population Study
Qadir, V. A., & Abdoulrahman, K. (2024) · ARO-The Scientific Journal of Koya University · doi:10.14500/aro.11526 · Cited by 4
Gold nanoparticles based colorimetric nanodiagnostics for cancer and infectious diseases
Valentini, P., Persano, S., Cecere, P., Sabella, S., & Pompa, P. P. (2014) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2039761 · Cited by 4
“The identification of point mutations is useful not only for the diagnosis of some genetic diseases and for the prognostic staging of cancer, but also for defining the appropriate therapeutic strategy as, in certain cases, their occurrence may predict the response to certain drug treatment.(34) The majority of mutatio…”
BackgroundQMC-PCRx: a novel method for rapid mutation detection
Ebili, H. O., Hassall, J., Asiri, A., Ham-Karim, H. A., Fadhil, W., Agboola, A., & Ilyas, M. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-204264 · Cited by 4
Chen, G., Kong, D., & Lin, Y. (2023) · Global Challenges · doi:10.1002/gch2.202200186 · Cited by 3
Gakinya, S. M., Njau, A. N., Abdallah, A., Nzioka, A. K., & Ogutu, J. O. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1433120 · Cited by 3
Rashidi, P., Bagheri, Z., Khodayar, Z., Tarkashvand, S., Elahirad, N., Akhoondi, R., Moghaddam, S. H., Sanati, M., Haghighatjou, R., Yekani, R., et al. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02085-8 · Cited by 3
Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer
Hendifar, A. E., Tan, C.-R., Annamalai, A., & Tuli, R. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.922881 · Cited by 4
“KRAS mutations, the vast majority of which are localized in codons 12 or 13, are constitutively active, leading to unregulated downstream functions [39].”
BackgroundRelevancia clínica del oncogén K-ras en cáncer de colon, experiencia en una población mexicana
Cabrera-Mendoza, F., Gainza-Lagunes, S., Castañeda-Andrade, I., & Castro-Zárate, A. (2014) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2014.07.002 · Cited by 3
Yang, K. M., Park, I. J., Lee, J. L., Yoon, Y. S., Kim, C. W., Lim, S., Kim, N. Y., Hong, S., Yu, C. S., & Kim, J. C. (2019) · Annals of Coloproctology · doi:10.3393/ac.2018.07.25 · Cited by 3
“As the present study focused on patients who underwent curative resection, evaluating the influence of tumor location was more feasible than in previous studies targeting patients with metastatic colorectal cancer, especially considering that the prognosis in the latter patients can easily be affected by the use of va…”
BackgroundSelf-citationGallegos‐Arreola, M. P., Garibaldi-Ríos, A. F., Cruz-Sánchez, J. I., Figuera, L. E., Ronquillo-Carreón, C. A., Reynoso, M. A. R., Gómez‐Meda, B. C., Carrillo-Dávila, I. A., Puebla‐Pérez, A. M., Montoya-Fuentes, H., et al. (2023) · Cells · doi:10.3390/cells12151941 · Cited by 3
“Consistent with their function, KRAS-targeting miRNA levels were found to be decreased in CRC, highlighting miRNAs as potential diagnostic or prognostic biomarkers, either as single factors or in miRNA panels [7].”
BackgroundInfluentialConstruction of an immune-related signature with prognostic value for colon cancer
Lv, Y., Wang, X., Ren, Y., Fu, X., Li, T., & Jiang, Q. (2021) · PeerJ · doi:10.7717/peerj.10812 · Cited by 3
“Additionally, microsatellite instability (MSI), KRAS and BRAF mutational status have also been considered as prognostic factors for colon cancers and may give clues for adjuvant therapy in the future (Boland & Goel, 2010; Arrington et al., 2012; Prahallad et al., 2012; Cullis, Das & Bar-Sagi, 2018).”
BackgroundVarshavi, D., Varshavi, D., McCarthy, N., Veselkov, K., Keun, H. C., & Everett, J. R. (2021) · Metabolomics · doi:10.1007/s11306-021-01852-w · Cited by 3
“KRAS mutations are associated with poor prognosis and resistance to targeted therapies, demonstrating the clinical importance of this gene (Arrington et al., 2012).”
BackgroundAssociation of G12D mutation in the KRAS gene with HPV and EBV in gastrointestinal cancer tissues
Hamidi, V., Shiadeh, A. E., Tabarraei, A., Nikoo, H. R., Sadeghi, F., Kamrani, G., Yahyapour, Y., & Moradi, A. (2024) · Journal of International Medical Research · doi:10.1177/03000605241302302 · Cited by 2
Understanding KRAS: mechanisms of resistance and future therapeutic strategies
Khashaba, R. M., Refaat, N. A., Elmorsy, S. E., Ali, F. I., & Magar, R. W. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07959-2 · Cited by 2
“Abnormal expressions of KRAS , as seen in many cancer patients, can drive tumor formation and promote disease progression [21, 22].”
Zhu, J., Chen, Z., Xi Tao, X. U., Wang, Y., Liu, P., Wen, M., Wang, Q., He, Y., Jin, H., Xue, H., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09285-0 · Cited by 3
Detection of KRAS, NRAS and BRAF Mutations in Liquid Biopsy from Patients with Colorectal Cancer
Ondraskova, K., Cwik, M., Horký, O., Berkovcová, J., Holčáková, J., Bartošík, M., Kazda, T., Mrazova, K., Uher, M., Kišš, I., et al. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.070116 · Cited by 2
Predictive and Prognostic Markers for Cancer Medicine
Yilmaz, E. Z., & Yörüker, E. E. (2020) · Wiley eBooks · doi:10.1002/9781119432487.ch6 · Cited by 2
A Pterin-FAM-TAMRA Tri-color Fluorescence Biosensor to Detect the Level of KRAS Point Mutation
Zeng, N., Guo, Y., & Xiang, J. (2020) · Analytical Sciences · doi:10.2116/analsci.20p265 · Cited by 2
Kim, S., Joo, M., Yeo, M., Cho, M.-J., Kim, J.-S., Jo, E., & Kim, J. (2021) · Oncology Letters · doi:10.3892/ol.2021.12969 · Cited by 2
Self-citationBrandão, G. R., Trindade, B. O., Flores, L. H. F., Motter, S. B., Alves, C. B., Remonti, T. A. P., Lucchese, A. M., Junior, A. D. P., & Kalil, A. N. (2023) · The American Surgeon · doi:10.1177/00031348231156763 · Cited by 2
“50,51 26-29 Therefore, we analyzed them separately: studies that included all RAS mutations and only KRAS mutations.”
MethodJayaraman, S., Montagne, J. M., Nirschl, T. R., Davis-Marcisak, E. F., Johnson, J., Huff, A. L., Hsiao, M.-H., Nauroth, J. M., Heumann, T. R., Zarif, J. C., et al. (2023) · Cell Reports Methods · doi:10.1016/j.crmeth.2023.100600 · Cited by 2
Fibroblasts Promote Resistance to KRAS Silencing in Colorectal Cancer Cells
Mendonça, S., Carvalho, P. D., Serra‐Roma, A., Oliveira, P., Ribeiro, A., Carvalho, J., Martins, F., Machado, A. L., Oliveira, M. J., & Velho, S. (2024) · Cancers · doi:10.3390/cancers16142595 · Cited by 3
“KRAS mutations occur in approximately 40% of colorectal cancers (CRCs) and are associated with a poor prognosis and resistance to therapy [1,2].”
BackgroundFactors affecting KRAS mutation detection in colorectal cancer tissue
Yun, H.-G., Lee, H. J., Kim, B., Lee, J.-H., Lee, J.-H., Lee, M.-Y., Kim, D., Sohn, J. H., Chae, S. W., Do, I. G., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.02.018 · Cited by 2
Nyoman, A. N., Wayan, J. I., & Sun, H. S. (2020) · Journal of Medical Sciences · doi:10.4103/jmedsci.jmedsci_205_19 · Cited by 2
eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancersPreprint
Waldron, J. A., Kanellos, G., Smith, R. C. L., Knight, J. R. P., Munro, J., Alexandrou, C., Vlahov, N., Pardo, L., Moore, M. H., Gillen, S. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.10.566546 · Cited by 2
Sir-Mendoza, F. J., Martínez, F. G., & Madera, M. (2021) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v71n1.95595 · Cited by 2
Shilika, E. P., Siyumbwa, S., Mwale, M., & Julius, P. (2022) · Medical Journal of Zambia · doi:10.55320/mjz.49.2.1113 · Cited by 1
Ryu, S., Baig, M. H., Panwar, U., Dong, J.-J., Jo, Y. S., Kim, C. J., Nale, S. D., Park, J., Ha, J., Moon, B., et al. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111437 · Cited by 1
Zweig, V., Goel, S., & Maitra, R. (2026) · World Journal of Clinical Oncology · doi:10.5306/wjco.v17.i2.113428 · Cited by 1
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
Balboa, E., Carracedo, Á., & Barros, F. (2014) · InTech eBooks · doi:10.5772/57172 · Cited by 1
“[132, 133] Global hypomethylation and hypermethylation of tumor, characterize epigenomic instability.”
BackgroundClinical relevance of the K-ras oncogene in colorectal cancer: Experience in a Mexican population
Cabrera-Mendoza, F., Gainza-Lagunes, S., Castañeda-Andrade, I., & Castro-Zárate, A. (2014) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2014.10.005 · Cited by 1
“Its use is reserved for wild-type K-ras patients only and is associated with other drugs such as capecitabine and oxaliplatin (XELOX regimen) or folinic acid and oxaliplatin (FOLFOX regimen).(16,17) It is important to know the clinical differences between the mutated and non-mutated groups in the local population, giv…”
BackgroundQian, Y. (2014) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 1
Tanrıverdi, Ö., Yılmaz, E. M., Menekşe, S., Çokmert, S., Oktay, E., Pilancı, K. N., Kocar, M., Avcı, N., Akman, T., Göksel, G., et al. (2016) · Journal of Oncological Sciences · doi:10.1016/j.jons.2016.07.001 · Cited by 1
“T4 8 (38) pN N0 3 (14) N1 5 (24) N2 6 (29) N3 7 (33) Stage Stage IIB 3 (14)”
Pharmacogenetics and Personalized Medicine
Paolo, A. D., Arrigoni, E., Galimberti, S., & Danesi, R. (2017) · Springer eBooks · doi:10.1007/978-981-10-5187-6_10 · Cited by 1
Classification of Colon Polyps and Risk of Neoplastic Progression
Cannizzaro, R., Magris, R., Maiero, S., Fornasarig, M., & Canzonieri, V. (2017) · Springer eBooks · doi:10.1007/978-3-319-59457-6_1 · Cited by 1
Saleh, I., Triwani, Hayati, L., Fatimah, L. S., & Subandrate, S. (2019) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1246/1/012051 · Cited by 1
Meng, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-809967-4.00008-9 · Cited by 1
Mouhcine, M., Kadil, Y., Segmani, I., Rahmoune, I., & Filali, H. (2024) · Current Computer - Aided Drug Design · doi:10.2174/0115734099264451231003172217 · Cited by 1
Bresam, S. (2024) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2024.2375091 · Cited by 1
“This aligns with previous research indicating codon 13 mutations represent about 50% of all KRAS mutations in (CRC) [31].”
KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer
Lei, L., Jiang, Z.-M., Li, C., & Lu, H. (2019) · Current Medical Science · doi:10.1007/s11596-019-2046-y · Cited by 1
Brändstedt, J. (2014) · Lund University Publications (Lund University) · Cited by 1
A cohort study of sex differences and prognostic biomarkers in colorectal cancer
Wangefjord, S. (2013) · Lund University Publications (Lund University)
Elsharkawy, A. M. (2015)
The Role of PI3K Signaling Pathway in Intestinal Tumorigenesis
Harris, J. W., Gao, T., & Evers, B. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19986-3_4
Understanding the role of KRAS-regulated autophagy in colorectal cancer: therapeutic implications
Francisco, R. A. B. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Rodríguez, C. C. (2017) · Gredos (University of Salamanca) · doi:10.14201/gredos.135769
Varma, A., Mathaiyan, J., & Shewade, D. G. (2018) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000178
“The presence of these KRAS mutations was found to be associated with the less or no clinical effectiveness of EGFR inhibitors [35].”
BackgroundInfluentialCurrent perspective on the treatment of advanced/metastatic colorectal cancer
John, S. (2020) · Onkologie · doi:10.36290/xon.2020.025
Ramadhan, R. S., & Algafari, R. N. (2018) · International Journal of Engineering & Technology · doi:10.14419/ijet.v7i4.37.23603
Nassir, R., & Esheba, G. E. (2021) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2021.96008
“KRAS and NRAS play an important role in regulating many cellular functions including cellular proliferation, apoptosis, migrations and differentiation [5] [6].”
BackgroundReynolds, I. S., O’Connell, E., McNamara, D. A., Prehn, J. H. M., Furney, S. J., & Burke, J. P. (2022) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-022-01144-x
“Mutations in these proteins result in continuous activation of the pathway, and this leads to progression of the cell cycle and eventually uncontrolled cellular growth [43, 44].”
Background
Metadata
- Authors
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J.
- Affiliations
- City Of Hope National Medical Center (US)
- University of Southern California (US)
- Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 11597, USA
- Corresponding author
- Arrington, Amanda K.
- Kim, Joseph
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-25
- Volume
- 13
- Issue
- 10
- Pages
- 12153-12168
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3497263
- OpenAlex
- W1991898744
- Cited by
- 244
- References
- 86
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 16 · 2021: 28 · 2020: 29 · 2019: 22 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 15 · 2014: 20 · 2013: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer, prognostic factors, predictive biomarkers, ras gene family, treatment resistance, tumor aggressiveness, survival
- MeSH terms
- Humans, Polymorphism, Genetic, Prognosis, Colorectal Neoplasms, ras Proteins, MicroRNAs, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


